Menu

Pioneering Heart Transplant Program Suspended

The move by Baylor St. Luke’s Medical Center follows an investigative news report detailing surgical errors and poor research practices.

Jun 4, 2018
Kerry Grens

ISTOCK, BARANOZDEMIRBaylor St. Luke’s Medical Center in Houston, a leading heart transplant center, has suspended its transplant program for two weeks, ProPublica and The Houston Chronicle reported jointly on Friday (June 1). The pause in operations comes within weeks of a damning investigative report by the two news outlets revealing extensive troubles with patient outcomes and research misconduct.

“I’m glad they are doing something,” Jennifer Lewis, whose husband died after a heart transplant and numerous follow-up surgeries at St. Luke’s, tells ProPublica and The Houston Chronicle. “That was my hope in speaking out and telling Lee’s story.”

In the case of Lewis’s husband, a mechanical failure in the operating room left the surgeon needing to hand-pump the patient’s newly transplanted heart for 10 minutes. A back-up defibrillator to jump-start the heart was not placed nearby, according to the surgeon, likely causing damage to the organ. The situation serves as an example of the transplant surgery performance at St. Luke’s in recent years: once a pioneering facility when transplants were first becoming available in the 1960s, it now ranks near the bottom in patient outcomes. “[T]wice as many St. Luke’s patients died within a year as would have been expected, taking into account patient characteristics and illnesses,” the news outlets state.

“Although extensive reviews are conducted on each unsuccessful transplant, the recent patient outcomes deserve an in-depth review before we move forward with the program,” Doug Lawson, CEO of the organization that owns St. Luke’s, says in a statement, according to ProPublica and The Houston Chronicle. “Our prayers are with the families, as well as all those on the waiting list.”

The journalists’ investigation also unearthed reports of research malpractice by one of the world’s leading developers of artificial hearts, Bud Frazier. A decade ago, St. Luke’s found that Frazier was implanting experimental devices into patients who didn’t qualify medically. The hospital had to repay millions of dollars of research funds to the U.S. government; none of this had been previously disclosed to the public.

Frazier is also accused of not disclosing conflicts of interest and failing to report problems with experimental heart pumps. “In the old days of medicine . . . that’s the way these guys did things,” Frank Smart, who worked with Frazier at Texas Heart, an affiliate of St. Luke’s, and who is now the chief of cardiology at Louisiana State University School of Medicine, tells ProPublica and The Houston Chronicle. “It was, ‘Well, I have an idea, and I’m the one that knows best, and by golly, I’m going to do it.’ And did that advance the field? Maybe. Is it the right thing to do? Absolutely not.”

See “If It Ain’t Broke . . .

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.